HEPATOLOGY: A home for hepatocellular cancer publications^†

• Pages: 1-2
• First Published: 24 June 2009

Alternative pathway therapy for hyperammonemia in liver failure^†‡

• Pages: 3-5
• First Published: 23 June 2009

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development^†

• Pages: 6-16
• First Published: 23 June 2009

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression^†

• Pages: 17-24
• First Published: 23 June 2009

Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A^†

• Pages: 25-33
• First Published: 23 June 2009

Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells^†‡

• Pages: 34-45
• First Published: 23 June 2009

Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference^†

• Pages: 46-55
• First Published: 23 June 2009

Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine^†

• Pages: 56-67
• First Published: 23 June 2009

Independent effects of physical activity in patients with nonalcoholic fatty liver disease^†

• Pages: 68-76
• First Published: 23 June 2009

Apolipoprotein B100 acts as a molecular link between lipid-induced endoplasmic reticulum stress and hepatic insulin resistance^†

• Pages: 77-84
• First Published: 23 June 2009

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice^†

• Pages: 85-93
• First Published: 23 June 2009

HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity^†‡

• Pages: 94-101
• First Published: 23 June 2009

Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma^†

• Pages: 102-112
• First Published: 23 June 2009

MicroRNA-195 suppresses tumorigenicity and regulates G₁/S transition of human hepatocellular carcinoma cells^†

• Pages: 113-121
• First Published: 23 June 2009

Chromodomain helicase/adenosine triphosphatase DNA binding protein 1–like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival^†

• Pages: 122-129
• First Published: 23 June 2009

Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells^†

• Pages: 130-142
• First Published: 23 June 2009

Bile salt–phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent^†

• Pages: 143-154
• First Published: 23 June 2009

L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats^†

• Pages: 155-164
• First Published: 23 June 2009

L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure^†‡

• Pages: 165-174
• First Published: 23 June 2009

Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population^†

• Pages: 175-184
• First Published: 23 June 2009

CCR2 promotes hepatic fibrosis in mice^†

• Pages: 185-197
• First Published: 23 June 2009

Toll-like receptor 3 signaling attenuates liver regeneration^†

• Pages: 198-206
• First Published: 23 June 2009

p21 is required for dextrose-mediated inhibition of mouse liver regeneration^†

• Pages: 207-215
• First Published: 23 June 2009

S6K1 deficiency protects against apoptosis in hepatocytes^†

• Pages: 216-229
• First Published: 23 June 2009

The etiology of liver damage imparts cytokines transforming growth factor β1 or interleukin-13 as driving forces in fibrogenesis^†

• Pages: 230-243
• First Published: 23 June 2009

Diferentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation^†

• Pages: 244-252
• First Published: 23 June 2009

Hypoxia-inducible factor 1α is up-regulated by oncostatin M and participates in oncostatin M signaling^†

• Pages: 253-260
• First Published: 23 June 2009

Hepatic recruitment of the inflammatory Gr1⁺ monocyte subset upon liver injury promotes hepatic fibrosis^†

• Pages: 261-274
• First Published: 23 June 2009

Single nucleotide polymorphism–mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency^†

• Pages: 275-281
• First Published: 23 June 2009

Protein or amino acid deprivation differentially regulates the hepatic forkhead box protein A (FOXA) genes through an activating transcription factor-4–independent pathway^†

• Pages: 282-290
• First Published: 23 June 2009

Primary biliary cirrhosis^†‡

• Pages: 291-308
• First Published: 23 June 2009

Health disparities in liver disease: Time to take notice and take action^†

• Pages: 309-313
• First Published: 24 June 2009

Albinism, cyclic neutropenia, and ceroid pigment in the liver^†

• Pages: 314-315
• First Published: 23 June 2009

Things that go BMP in the liver: Bone morphogenetic protein 6 and the control of body iron homeostasis^†

• Pages: 316-319
• First Published: 23 June 2009

Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development^†

• Page: 320
• First Published: 23 June 2009

Reply:^†

• Page: 320
• First Published: 23 June 2009

Orlistat for overweight subjects with nonalcoholic steatohepatitis^†

• Page: 321
• First Published: 23 June 2009

Reply:^†

• Pages: 321-322
• First Published: 23 June 2009

Diagnosis, management, and treatment of hepatitis C^†

• Page: 322
• First Published: 23 June 2009

Management of patients with hepatitis C virus genotype 2 or 3: Comments on updated american association for the study of liver diseases practice guidelines^†

• Page: 323
• First Published: 23 June 2009

Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: Treating active drug users^†

• Pages: 323-324
• First Published: 23 June 2009

Reply:^†

• Pages: 324-325
• First Published: 23 June 2009

Serum Golgi Phosphoprotein 2 level: A better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma^†

• Page: 325
• First Published: 23 June 2009

Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas^†

• Page: 326
• First Published: 23 June 2009

• Pages: 326-327
• First Published: 23 June 2009

Reply:^†

• Pages: 327-328
• First Published: 23 June 2009

Utility of magnetic resonance imaging in the evaluation of hepatic fat content^†

• Pages: 328-329
• First Published: 23 June 2009

Reply:^†

• Page: 329
• First Published: 23 June 2009

Screening for Wilson's disease in acute liver failure: A comparison of currently available diagnostic tests^†

• Page: 329
• First Published: 23 June 2009

Interleukin-17–targeted treatment of alcoholic liver disease^†

• Pages: 329-330
• First Published: 23 June 2009

• Page: 331
• First Published: 24 June 2009

• Page: 331
• First Published: 24 June 2009